Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson’s Disease

Publisher： Karger

E-ISSN： 1421-9913|62|1|40-48

ISSN： 0014-3022

Source： European Neurology, Vol.62, Iss.1, 2009-04, pp. : 40-48

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 1, Iss. 1, 2011-06 ,pp. : 163-179

Karger

Access to resources Recommend Favorite

Is Dopamine Agonist Therapy Associated with Developing Pathological Gambling in Parkinson’s Disease Patients?

By  

European Neurology, Vol. 59, Iss. 3-4, 2008-01 ,pp. : 183-186

Karger

Access to resources Recommend Favorite

Efficacy and Safety of Simultaneous Bilateral Pallidotomy in Advanced Parkinson’s Disease

By  

European Neurology, Vol. 56, Iss. 2, 2006-09 ,pp. : 113-118

Karger

Access to resources Recommend Favorite

Efficacy and Tolerability of Entacapone as Adjunctive Therapy to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Deterioration in Daily Medical Practice: An Open, Multicenter Study

By  

European Neurology, Vol. 45, Iss. 2, 2001-02 ,pp. : 111-118

Karger

Access to resources Recommend Favorite

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

By Nyhlin H.   Bang C.   Elsborg L.   Silvennoinen J.   Holme I.   Rüegg P.   Jones J.   Wagner A.  

Scandinavian Journal of Gastroenterology, Vol. 39, Iss. 2, 2004-02 ,pp. : 119-126

Informa Healthcare

Access to resources Recommend Favorite